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Abstract Immunoglobulin production stimulating factor-Ilo~, 
which enhances immunoglobulin production of human and mouse 
hybridomas was purified from cell lysate of human Burkitt's 
lymphoma, Namalwa cells, and identified as glyceraldehyde-3- 
phosphate dehydrogenase. The enhancement of immunoglobulin 
production with this enzyme was not linked with its enzymatic 
activity. The enzyme enhanced immunoglobulin productivity of 
transcription-suppressed hybridomas, but did not enhance that of 
translation-suppressed hybridomas. From these results, it is sug- 
gested that this enzyme takes part in the post-translational con- 
trol or the enhancement of translation activity to stimulate immu- 
noglobulin production of hybridomas. 
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subunit is highly homologous to that of glyceraldehyde-3-phos- 
phate dehydrogenase (GAPDH) of various origins, which is a 
key enzyme in the glycolytic pathway [4]. IPSF-IIfl was also 
identified as a 46 kDa protein of which the partial amino acid 
sequence corresponded with the human enolase c~-chain as re- 
ported previously [5]. As well as GAPDH, enolase isan enzyme 
involved in the glycolytic pathway, 
GAPDH derived from rabbit muscle nhances IgM produc- 
tion of human human hybridomas about 10-fold in serum-free 
medium. IgM production of various human-human and 
mouse-mouse hybridomas are stimulated by the addition of 
this enzyme. 
Here we report, how GAPDH stimulates immunoglobulin 
production of hybridomas. 
2. Materials and methods 
1. Introduction 
Monoclonal antibodies (MAbs) have been widely applied to 
various areas, including diagnosis, therapy, immunohistochem- 
istry, and industrial fields to purify products by immunoaffinity 
chromatography. For therapeutic application of MAbs, human 
MAbs are desirable, because only the human MAbs negate the 
serious problems associated with immunogemic disorders 
caused by heteroantibodies. Increased emands for human 
MAbs 'have prompted attents to' improve the cellular produc- 
tivity of human-human hybridomas to meet the demand for 
human MAbs. We have searched for cellular protein factors 
that enhance immunoglobulin production of hybridomas to 
accomplish the stimulation of cellular productivity under 
serum-free conditions. Several factors termed immunoglobulin 
production stimulating factor (IPSF) were discovered in cell 
extracts or culture medium. IPSF-I was discovered in culture 
medium from a human lymphoblastoid cell line HO-323 [1], 
and IPSF-II was purified from cell lysate of human Burkitt's 
lymphoma, Namalwa cells [2,3]. The previous data revealed 
that the Namalwa cell lysate contained two IPSF active sub- 
stances, IPSF-Ikx and -II,8, respectively. IPSF-II~ was com- 
pletely purified and identified as a 112 kDa protein that has a 
subunit structure composed of a 40 kDa polypeptide chain and 
two homogeneous 36 kDa polypeptide chains. The 36 kDa 
subunit exclusively showed IPSF activity. On the other hand, 
the 40 kDa protein showed neither IPSF activity nor the syner- 
gistic effect of the IPSF activity of the 36 kDa subunit. The 
sequence of 20 amino acids from the N-terminus of the 36 kDa 
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2.1. Cells and cell culture 
A human human hybridoma cell line, HB4C5 was used to assay 
immunoglobulin production stimulating activity of GAPDH. HB4C5 
cells, which produce human lung cancer specific monoclonal IgM, were 
fusion products of a human lymphocyte and a human fusion partner 
NAT-30 cells [6]. HB4C5 cells were maintained in ERDF medium 
(Kyokuto Pharmaceutical, J pan) supplemented with 10/.tg/ml of insu- 
lin, 20/lg/ml of transferrin, 20/IM ethanolamine and 25 nM sodium 
selenite (ITES-ERDF) at 37°C under humidified atmosphere of 5% 
COJ95% air [7]. 
2.2. Assay of lPSF activity 
IPSF activity was examined by measuring the amount of immuno- 
globulin secreted by HB4C5 cells in the cultured medium. HB4C5 cells 
were inoculated at 1 x 105 cells/ml in a 96-well plate containing 200 ,ul 
of ITES-ERDF medium supplemented with GAPDH derived from 
rabbit muscle (Boehringer Mannheim, Germany). After incubation i  
the CO2-incubator, the amount of IgM in each culture medium was 
measured by enzyme-linked immunosorbent assay (ELISA) using anti- 
human IgM antibody as mentioned previously [2]. 
2.3. Assay of enzymatic a tivity of GAPDH 
GAPDH catalyzes conversion ofglyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate, in the presence ofNAD + and arsenate. Reaction 
mixture composed of 0.1 M disodium arsenate, 0.5 mM NAD ÷, 5 
mM glyceraldehyde-3-phosphate, 3.5 mM cysteine, 26 mM sodium 
pyrophosphate (pH 8.4), and 0.1 /.tg/ml of GAPDH. The produced 
NADH by the enzymatic reaction can be quantitatively monitored by 
spectrophotometrical measurement at 340 nm [8]. 
2.4. J-"~l-labeling of GAPDH 
GAPDH derived from rabbit muscle was labeled with ~2sI-iodine by
the immobilized lactoperoxidase: a glucose oxidase method (Radio 
iodination system; New England Nuclear, USA) as according to man- 
ufacturer's directions. One mg of GAPDH was used for the labeling 
reaction. After the labeling reaction, the reaction mixture was gel fil- 
trated with a Sephadex G-25 column (Pharmacia, Sweden) equilibrated 
with 10 mM sodium phosphate buffer (pH 7.4) to remove free radioiso- 
tope. 
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2.5. Act-D treatment of hybridomas 
Hybridoma, HB4C5 cells were treated with 4/.tg/ml of actinomycin 
D (Act-D) for 2 h at 37°C under humidified atmosphere of 5% CO2/95% 
air to suppress their transcription activity of the hybridoma. After 
Act-D treatment, these cells were washed twice with ERDF medium, 
and inoculated toexamine the IPSF effect of GAPDH on transcription- 
suppressed hybridomas. 
2.6. Cyeloheximide treatment of hybridomas 
HB4C5 cells were pre-incubated in ITES-ERDF medium supple- 
mented with 10 Hg/ml of cyeloheximide for5 h to suppress their trans- 
lation activity. Following pre-incubation, cells were washed twice with 
ERDF medium and cultured in ITES-ERDF medium with or without 
10 Hg/ml of cyeloheximide to determine the IPSF effect of GAPDH on 
translation-suppressed hybridomas. 
3. Results 
3~ 1. Correlation between enzymatic and IPSF activity of 
GAPDH 
GAPDH catalyzes the conversion of glyceraldehyde-3-phos- 
phate into 1,3-bisphosphoglycerate, nd a high energy phos- 
phate compound is generated in this oxidation-reduction reac- 
tion. The first point for discussion regarding IPSF activity of 
GAPDH is whether the enzymatic activity of this enzyme takes 
part in its IPSF activity. Iodine-labeled GAPDH was used to 
investigate his question, and it completely ost catalytic activity 
(Fig. 1A). It is supposed that GAPDH is inhibited in its enzy- 
matic activity by the modification of the SH-group of its active 
center during the iodine-labeling reaction. However, the IPSF 
activity of this enzyme was completely retained in spite of 
inactivation of its enzymatic function as shown in Fig. lB. 
These results make it clear that the IPSF activity of GAPDH 
is derived from neither its enzymatic activity nor reaction prod- 
ucts. These results also provide an indication that this enzyme 
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has another function other than enzymatic one in the glycolytic 
pathway. 
3.2. Time-course of enhancement of immunoglobulin production 
by GAPDH 
At first, the time-course effect of GAPDH on IgM produc- 
tion of HB4C5 cells was examined to investigate the mode of 
action of GAPDH as IPSF-IIc~, GAPDH was added to ITES- 
ERDF medium at the concentration of 50/~g/ml, at which 
GAPDH shows maximal enhancement of activity against 
HB4C5 cells as shown in Fig. lB. HB4C5 cells were facilitated 
in their IgM production by GAPDH immediately after inocula- 
tion, and the IPSF effect was maintained for 30 h as shown in 
Fig. 2. Immunoglobulin production of HB4C5 cells was en- 
hanced 6.6-13.5-fold throughout the cultivation period. Previ- 
ous work has proved that the IPSF activity of GAPDH contin- 
ues over 3 days until the culture conditions of the hybridomas 
deteriorate due to a deficiency of nutrients and an accumula- 
tion of metabolites [3]. GAPDH did not stimulate the growth 
rate of the hybridoma t all. These results reveal that GAPDH 
enhances immunoglobulin productivity ofeach hybridoma cell. 
3.3. Effect of GAPDH on transcription-suppressed hybridomas 
HB4C5 cells treated with 4/lg/ml of Act-D for 2 h were used 
to determine the IPSF effect of GAPDH on transcription- 
suppressed hybridomas. Transcription-suppressed HB4C5 cells 
were inoculated in ITES-ERDF medium supplemented with 50 
/lg/ml GAPDH. The Act-D treated HB4C5 cells cultured with- 
out GAPDH were still unable to produce immunoglobulin 6 h
after inoculation, as shown in Fig. 3. On the other hand, the 
IPSF effect of this enzyme on transcription-suppressed HB4C5 
cells was observed immediately after inoculation as well as that 
on non-suppressed cells. The accumulation of IgM secreted in 
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Fig. 1. Enzymatic and IPSF activities of iodine-labeled GAPDH. GAPDH catalyzes conversion ofglyceraldehyde-3-phosphate to 1,3-bisphosphoglyc- 
erate in the presence ofNAD ÷ and arsenate. The enzymatic reaction of 25/lg/ml of iodine-labeled (O) and native GAPDH (~;) can be quantitatively 
monitored by spectrophotometrically measuring the quantity of produced NADH at 340 nm at room temperature (section A). IPSF activity of various 
concentrations of iodine-labeled (O) and native enzyme (©) were measured as described insection 2 (section B). The open square represents IgM 
productivity of HB4C5 cells in ITES-ERDF medium without GAPDH. Results are expressed asthe mean of two experiments. 
94 Z Sugahara et al./FEBS Letters 368 (1995) 92-96 
200 
18o 
160 
.L 
E 
f. 120  
o 
,~ 1.. 
L. 
20 
A ~  . . ! 
0 4 a 12 16 20  24  28  32  
Cultivation t lme ( hour ) 
Fig. 2. Time-course of IPSF activity of GAPDH on IgM production 
of human-human hybridoma HB4C5 cells. IgM production of HB4C5 
cells was measured in the presence of50gtg/ml of GAPDH derived from 
rabbit muscle (0) on each sampling time. Secreted and accumulated 
IgM amount was measured by ELISA. The closed circle (e) represents 
IgM production of the hybridoma cultured in ITES-ERDF medium 
without GAPDH. Results represent the mean + S.D. of three independ- 
ent measurements. 
the medium linearly increased for 6 h. GAPDH finally en- 
hanced immunoglobulin productivity of Act-D treated HB4C5 
cells by 8-fold. Transcriptional suppression of the hybridoma 
did not influence the IPSF effect of GAPDH at all. If GAPDH 
acted on pre-transcriptional and/or transcriptional processes, 
the IPSF effect of this enzyme would not be observed. From 
these results, it is supposed that GAPDH acts on the post- 
transcriptional process of protein synthesis to enhance immu- 
noglobulin productivity of the hybridoma. 
3.4. Effect of  GAPDH on translation-suppressed hybridomas 
The IPSF effect of GAPDH on translation-suppressed 
HB4C5 cells was examined to confirm whether the enzyme acts 
on post-transcriptional process. Suppression of the translation 
activities of HB4C5 cells was accomplished by cycloheximide 
treatment. After pre-incubation f the hybridoma with I0/ag/ 
ml cycloheximide, assay of the IPSF activity was performed in 
ITES-ERDF medium containing cycloheximide, to investigate 
the effect of GAPDH under translation-suppressed conditions 
as shown in Fig. 4A. The inhibition of the translation activity 
of HB4C5 cells caused a loss of the IPSF effect of GAPDH. On 
the other hand, the IPSF assay performed without cyclo- 
heximide showed that HB4C5 cells re-activated their transla- 
tion activities and were clearly accelerated in their immuno- 
globulin productivity by the addition of GAPDH (Fig. 4B). 
There was no evidence for the loss of IPSF activity of GAPDH. 
If this enzyme acted on the post-translational process, such as 
secretion, the IPSF activity should be observed under transla- 
tion-suppressed conditions. These results provide vidence that 
GAPDH participates in the post-transcriptional process or the 
translational control of protein synthesis to enhance IgM pro- 
ductivity. 
4. Discussion 
We have previously reported that immunoglobulin produc- 
tion stimulating factor-Ilct (IPSF-IIa) was purified from ex- 
tracts of human Burkitt's lymphoma, Namalwa cells [3]. 1PSF- 
l Ia was a 112 kDa protein composed of two homogeneous 36
kDa polypeptides and a 40 kDa polypeptide. The 36 kDa sub- 
unit that exclusively retained IPSF activity was identified as 
GAPDH, a key enzyme in the glycolytic pathway, on the basis 
of its N-terminal amino acid sequence and enzymatic activity 
[4]. The enzymes from other origins, such as rabbit muscle, 
human erythrocyte, and Bacillus stearothermophius stimulated 
IgM production of human-human d mouse-mouse hybrido- 
mas under serum-free conditions. 
Then, the mode of actions of GAPDH on enhancement of 
immunoglobulin production was investigated. The enzyme 
completely ost its enzymatic activity during the iodine labeling 
reaction. However, iodine-labeled GAPDH still had the same 
stimulatory activity for immunoglobulin production as native 
GAPDH. It was proved from these results that the IPSF activ- 
ity of this enzyme was irrelevant to its enzymatic function or 
reaction products in the glycolysis. This also indicates that 
GAPDH has another biological function besides its enzymatic 
activity. 
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Fig. 3. IPSF effect of GAPDH on transcription-suppressed HB4C5 
cells. HB4C5 cells treated with 40 J~g/ml of actinomycin D for 2 h were 
cultured with 50 ~g/ml of GAPDH derived from rabbit muscle in 
ITES-ERDF medium and IgM concentration f the cultured medium 
was quantified. Each symbol shows IgM accumulation in the medium 
containing GAPDH (O) or not (e). Results are expressed as the 
mean _+ S.D. of three independent measurements. 
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Fig. 4. IPSF effect of GAPDH on translation-suppressed HB4C5 cells. HB4C5 cells were cultured in ITES-ERDF medium containing 10/lg/ml of 
cycloheximide toinhibit heir translation activity during pre-incubation for 5 h. (A) After pre-incubation, the IPSF activity of GAPDH was assayed 
with 10 flg/ml of cycloheximide tocontinue to inhibit translation activity. (B) After pre-incubation with cycloheximide the IPSF assay performed 
without cycloheximide to reactivate translation activity. Each symbol shows IgM accumulation i the medium containing GAPDH (;~) or not (e). 
Results shown in (A) and (B) represent the mean _+ S.D. of three independent measurements. 
A human-human hybridoma cell line, HB4C5 cells started 
to increase IgM production as soon as GAPDH was added to 
the medium, and the accelerated production was maintained 
for 3 days until the conditions of the hybridomas became worse 
due to a deficiency of nutrition and accumulation of cytotoxic 
metabolites. GAPDH stimulated the immunoglobulin produc- 
tion without any growth stimulating effects, so that the enzyme 
facilitated secretion or immunoglobulin production of the hy- 
bridomas. However, only a small amount of immunoglobulin 
was detectable inside HB4C5 cells in comparison with their 
productivity. This indicates that most of the immunoglobulin 
molecules are consitutively secreted by these hybridoma cells. 
This circumstantial evidence implies that the process of immu- 
noglobulin secretion is not affected by GAPDH, and the en- 
zyme enhances immunoglobulin productivity of each hybrid- 
oma cell and acts on the protein synthesis of the cell. This 
hypothesis also supported by the results hown in Fig. 2 that 
indicates the durable stimulation of the immunoglobulin pro- 
ductivity. 
The effect of GAPDH on transcription-suppressed hybrido- 
mas was examined to investigate how this enzyme affected the 
immunoglobulin synthesis of the hybridoma. GAPDH stimu- 
lated immunoglobulin productivity of HB4C5 cells in spite of 
the inhibition of the transcription activity. This result indicates 
that GAPDH does not accelerate transcription of RNA mole- 
cules. The immediate IPSF effect of GAPDH on Act-D treated 
HB4C5 cells suggests that the enzyme does not stabilize the 
mRNA for immunoglobulin molecule to enhance the produc- 
tivity. This is also supported by the fact that the immunoglob- 
ulin mRNA level in HB4C5 cells was not increased by the 
treatment with GAPDH [4]. All these results suggest hat the 
immunoglobulin production stimulating activity of GAPDH is 
not derived from acceleration of the transcription process. Fur- 
ther investigation revealed that GAPDH was not able to stim- 
ulate immunoglobulin productivity of translation-suppressed 
hybridomas. This fact suggests that this enzyme facilitates 
translation activity of the hybridoma to enhance immunoglob- 
ulin production. In conjunction with the stimulation of the 
translation activity, GAPDH was added to the rabbit reticulo- 
cyte cell-free translation system to examine the effect of the 
enzyme on this system. The translation of immunoglobulin 
peptide was enhanced 1.5-fold by the addition of this enzyme 
[9]. However, translation stimulating effect of GAPDH on the 
cell-free translation system was much lower than that on intact 
cells. Some reasons could be suggested for the lower IPSF 
activity of the enzyme in cell-free translation. First, it comes 
from essential features of the cell-free translation system, is that 
the cell-free translation system is inferior to in vivo translation 
and exhibits only limited translation activity. Second, the cell- 
free translation systems contain endogenous GAPDH [10], so 
that the further enhancing effect was not observed by elevated 
concentrations of this enzyme. Finally, the most possible rea- 
son, that GAPDH may be a precursor of the IPSF active 
substance, and some modification, such as enzymatic digestion, 
is necessary for GAPDH to act as IPSF. This hypothesis could 
also explain why the endogenous GAPDH does not enhance 
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immunoglobulin productivity of the hybridoma. We suppose 
that GAPDH would have to be extracellularly added and mod- 
ified to stimulate immunoglobulin productivity of the hybrid- 
oma.  
GAPDH has been studied by many workers for its associat- 
ing property with cytoplasmic membrane proteins and cellular 
organelles, such as human erythroid cell membrane [11-14], 
plasma membrane of the intact human red blood cell [15], 
microtubules of a human colon tumor cell line [16], the rod 
outer segment of retinal rod photoreceptor cell [17], and calse- 
questrin of skeletal muscle [18]. The enzyme has a specific 
affinity for highly acidic regions of certain proteins and the 
association of the enzyme with these organelles i inhibited by 
physiological ionic strength [13,18]. We, however, investigate 
the existence of receptors for GAPDH on the surface of the 
hybridoma, and the existence of a specific receptor was not 
verified (data not shown). From this result, it is supposed that 
GAPDH associates with the surface of the hybridoma in the 
same way as with the cytoplasmic membranes or cellular organ- 
elles. 
Besides these functions which are mentioned previously, 
GAPDH has other properties, too. The enzyme associates with 
single-stranded DNA [19], RNA [20] and mono- and polyri- 
bosomes [21]. Moreover, this enzyme is one of the three major 
RNA-binding proteins of rabbit reticulocytes [10]. We suppose 
that these features of this enzyme are concerned with the 1PSF 
activity of the enzyme, because some DNA-binding proteins, 
such as histone HI, H2A, and H2B, have IPSF activities [22]. 
In addition, lactate dehydrogenase which associates with sin- 
gle-stranded DNA [23] also has IPSF activity (Sugahara et al., 
in press). From these results, it is assumed that the enzyme 
associates with the surface of HB4C5 cells in an electrostatic 
manner. Following this, the enzyme is internalized by pinocyto- 
sis, and modified by degradative enzymes in lysosomes to serve 
as IPSF. The modified GAPDH stimulates the translation ac- 
tivity of hybridoma. 
There is one finding that GAPDH mRNA is a major inter- 
leukin 2- induced transcript in the helper-T lymphocyte, and the 
translation of the GAPDH mRNA was enhanced [24]. This 
finding makes us consider the possibility that the enzyme is 
produced by IL-2 activated helper-T lymphocytes, and its en- 
hances immunoglobulin productivity of plasma cells in vivo. 
Because the enzyme can also strongly enhance immunoglobulin 
productivity of peripheral blood lymphocytes (manuscript in 
preparation). However, this hypothesis contains the inconsis- 
tency that the enzyme is an intercellular protein, hence that the 
enzyme is not usually secreted outside of the cell. Uncovering 
the mechanisms of the actions of GAPDH will contribute not 
only to the effective nhancement of cellular productivities of 
immunoglobulin of hybridomas, but also to the interpretation 
of the regulation of protein synthesis in animal cells. 
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